Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel ...

Ipsen has entered an exclusive global licensing agreement with Foreseen Biotechnology for FS001, a potentially first-in-class antibody-drug conjugate (ADC). This partnership grants Ipsen worldwide ...

These days, a whole lot of really great bands have been exploring the sound of late-'80s crossover thrash -- the moment where the hardcore and metal undergrounds sort of put their heads down, charged ...

Ipsen is back with its second antibody-drug conjugate (ADC) deal of the year, this time signing a $1 billion biobucks pact with Foreseen Biotechnology for a preclinical solid tumor candidate. The ...

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bio. Under ...

Ipsen is spreading its bets in a fast-growing and competitive area of cancer drug research, striking a deal for a novel Foreseen Biotechnology antibody drug conjugate (ADC) that’s on track for its ...

Ipsen and Foreseen Biotechnology have entered into an exclusive global licensing agreement worth up to $1.03bn for a preclinical antibody-drug conjugate (ADC). The deal gives Ipsen exclusive worldwide ...

Ipsen SA and Foreseen Technology (Beijing) Co. Ltd. have entered into an exclusive global licensing agreement for FS-001, an antibody-drug conjugate (ADC) that targets a novel tumor-associated antigen ...

Foreseen come from Helsinki, and they make a rabidly fast, ugly, lo-fi version of old-school crossover thrash. It’s dirty, ugly, violent music — the kind of thing that grabs you by your entrails and ...